Given the higher incidence of single or combined EGFR-mutations in East-Asian NSCLC populations, most of the findings and interpretations on the effect of EGFR co-mutations (called complex mutations by some authors) on TKI-treatment come from studies in East-Asian cohorts. This evidence concerns the gene EGFR and non-small cell lung carcinoma.